ResultsIQ

ResultsIQ › Latest results › Syngene International Limited

Syngene International Limited Q3 FY26 results deck summary

NSE: SYNGENE · BSE: 539268

Results deck of 23 Jan 2026, summarised by AI from the filing.

PAT before exceptional items ₹729 mn, down 44% YoY; PAT after exceptional items ₹150 mn, down 89% YoY.

Key takeaways

  1. Q3 FY26 PAT PAT before exceptional items ₹729 mn, down 44% YoY; PAT after exceptional items ₹150 mn, down 89% YoY.
  2. BMS extension Bristol Myers Squibb extended its partnership with Syngene through to 2035, broadening integrated services across the drug development lifecycle.
  3. New capabilities Syngene commissioned a commercial-scale liquid-filled hard gelatin capsule facility and expanded advanced chemistry capabilities at Hyderabad.

Original filing on BSE

Syngene International Limited Q1 FY27 results

As filed: Revenue ₹736 cr (−16% year on year), EBITDA ₹90.8 cr (−56% year on year), PAT −₹9.0 cr (−106% year on year), EBITDA margin 12.3% (−1,000 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,037 cr (+2% year on year), EBITDA ₹303 cr (−12% year on year), PAT ₹148 cr (−19% year on year), EBITDA margin 29.3% (−452 bps). Score 39 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 452 bps year on year. Share price after the results: +2.3% in 30 days (Nifty 500: −0.9%).
  • Q3 FY26: Revenue ₹917 cr (−3% year on year), EBITDA ₹209 cr (−26% year on year), PAT ₹15.0 cr (−45% year on year), EBITDA margin 22.8% (−727 bps). Score 8 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit before exceptional items growth were well below it. EBITDA margin fell 727 bps year on year. Other income 54% of PBT. Tax rate 47%. Share price after the results: −24.0% in 29 days (Nifty 500: +1.7%).
  • Q2 FY26: Revenue ₹911 cr (+2% year on year), EBITDA ₹200 cr (−18% year on year), PAT ₹67.0 cr (−37% year on year), EBITDA margin 22.0% (−543 bps). Score 23 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 543 bps year on year. Profit fell 23% from last quarter. Share price after the results: −1.0% in 30 days (Nifty 500: +0.7%).
  • Q1 FY26: Revenue ₹875 cr (+11% year on year), EBITDA ₹206 cr (+21% year on year), PAT ₹87.0 cr (+14% year on year), EBITDA margin 23.5% (+202 bps). Score 71 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 202 bps year on year. Tax rate 15%. Revenue fell 14% from last quarter. Share price after the results: −1.3% in 30 days (Nifty 500: −1.4%).
  • Q4 FY25: Revenue ₹1,018 cr (+11% year on year), EBITDA ₹344 cr (+9% year on year), PAT ₹183 cr (−3% year on year), EBITDA margin 33.8% (−78 bps). Score 61 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit growth was in line with it. EBITDA margin fell 78 bps year on year. Share price after the results: −14.9% in 30 days (Nifty 500: +2.4%).
  • Q3 FY25: Revenue ₹944 cr (+11% year on year), EBITDA ₹284 cr (+22% year on year), PAT ₹131 cr (+17% year on year), EBITDA margin 30.1% (+292 bps). Score 84 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 292 bps year on year.
  • Q2 FY25: Revenue ₹891 cr (−2% year on year), EBITDA ₹244 cr (−4% year on year), PAT ₹106 cr (−9% year on year), EBITDA margin 27.4% (−53 bps). Score 26 of 100, Below trend. EBITDA margin fell 53 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Syngene International Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.